Business
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
ORLANDO, FL / ACCESSWIRE / April 4, 2023 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery ("Kindeva") have selected the
About this update from Nutriband Inc.
[{"type":"text","content":"ORLANDO, FL / ACCESSWIRE / April 4, 2023 / Nutriband Inc.(\"Company\") (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery (\"Kindeva\") have selected the target AVERSA™ formulation to take forward into commercial scale manufacturing process development for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology which can be manufactured using standard commercial transdermal manufacturing processes and is currently available for incorporation into a variety of transdermal patch products.AVERSA™ Fentanyl combines Nutriband's proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva's FDA-approved transdermal fentanyl patch system. AVERSA™ Fentanyl was recently estimated to have the potential to reach peak annual US sales of $80M - $200M.1\"We continue to make great progress with the team at Kindeva Drug Delivery in the development of Aversa Fentanyl, which has the potential to be the first abuse deterrent pain patch on the market,\" said Gareth Sheridan, CEO, Nutriband.\"Partnering together to formulate and develop combination products for patients worldwide is core to our business,\" said Kindeva CEO Milton Boyer. \"We appreciate Nutriband's expertise and partnership - which is complementary to Kindeva's broad range of drug-device expertise that spans transdermal routes of administration - as we take this important next step together in development.\" Nutriband's AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to help prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these kinds of treatments remain accessible to patients that really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.1 Health Advances market analysis report 2022About Nutriband Inc.We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is ...